论文部分内容阅读
Aims: Non-small cell Cancer(NSCLC)is the leading cause of cancer-related deaths in the worldwide.The most lethality in NSCLC is due to uncontrolled tumor metastasis(e.g.,brain,bone and hepar metastasis).Epidermal growth factor receptor(EGFR)has been confirmed to be an effective biomarker in EGFR-tyrosine kinase inhibitors(TKIs)treatment for advanced NSCLC.